Randomized Trial of Cisplatin and Carboplatin versus Cisplatin, Vinblastine and Bleomycin in Ovarian CancerKikkawa F.a · Matsuzawa K.b · Arii Y.c · Kawai M.c · Kobayashi I.d · Nakashima N.e · Mizutani S.a
Departments of Obstetrics and Gynecology,aNagoya University School of Medicine, Nagoya, bAnjo Kosei Hospital, Anjo, cToyohashi City Hospital, Toyohashi, dNagoya Daini Red Cross Hospital, and eDepartment of Laboratory Medicine, Nagoya University School of Medicine, Nagoya, Japan
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Between January 1992 and July 1997, 202 cases of epithelial ovarian cancer were registered and assigned randomly to a combination of cisplatin and carboplatin (PP group), or cisplatin, vinblastine and bleomycin (PVB group). We analyzed 189 patients whose clinical records were available. The PP chemotherapeutic regimen was advantageous in terms of overall survival compared to the PVB regimen until 4 years after the initial operation. However, the 5-year survival rates were almost the same in both groups. However, in stage III patients, the mean survival time in the PP group was 51.4 months and that in the PVB group was 23.3 months, and there was a statistically significant difference in the survival curves between the two groups (p = 0.0158). The 5-year survival rates were 31.1 and 20.4% in the PP and PVB groups, respectively, in stage III patients. The PP regimen was also significantly superior in patients with macroscopic residual tumor after the initial operation, and the 5-year survival rates were 25.7 and 10.1% in the PP and PVB groups, respectively (p = 0.0128). However, there was no significant difference between the two regimens in patients without macroscopic residual tumor. Cox’s proportional hazards regression analysis showed that tumor stage, presence of macroscopic residual tumor, and the chemotherapeutic regimen used were significant prognostic factors. In conclusion, the PP chemotherapeutic regimen is superior to the PVB regimen especially in the treatment of advanced ovarian cancer.
© 2000 S. Karger AG, Basel
- Omura G, Blessing JA, Ehrlich CE, Miller A, Yordan E, Creasman WT, Homesley HD: A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer 1986;57:1725–1730.
- Menczer J, Ben-Baruch G, Rizel S, Brenner H: Intraperitoneal chemotherapy versus no treatment in patients with ovarian carcinoma who are in complete clinical remission. Cancer 1992;70:1956–1959.
- Janicke F, Holscher M, Kuhn W, Hugo RV, Pache L, Siewert JR, Graeff H: Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer 1992;70:2129–2136.
- Kikkawa F, Ishikawa H, Tamakoshi K, Suganuma N, Mizuno K, Kawai M, Arii Y, Tamakoshi A, Kuzuya K, Tomoda Y: Prognostic evaluation of lymphadenectomy for epithelial ovarian cancer. J Surg Oncol 1995;60:227–231.
- Marsoni S, Torri V, Valsecchi MG, Belloni C, Bianchi U, Bolis G, Bonazzi C, Colombo N, Epis A, Favalli G, Gambino A, Landoni F, Maggi R, Pecorelli S, Presti S, Vasseno L, Zanaboni F, Mangioni C (GICOG): Prognostic factors in advanced epithelial ovarian cancer. Br J Cancer 1990;62:444–450.
- Fanning J, Bennett TZ, Hilger RD: Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma. Obstet Gynecol 1992;80:954–960.
- Waterhouse DM, Reynolds RK, Natale RB: Combined carboplatin and cisplatin. Cancer 1993;71:4060–4066.
Lund B, Hansen M, Hansen OP: High dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian cancer patients with residual disease. J Clin Oncol 1987;7:1469–1473.
- Piccart MJ, Nogaret JM, Marcelis L, Longree H, Ries F, Kains JP, Gobert P, Domange AM, Sculier JP, Gompel C: Cisplatin combined with carboplatin: A new way of intensification of platinum dose in the treatment of advanced ovarian cancer. J Natl Cancer Inst 1990;82:703–707.
- Morikawa Y, Kawai M, Kano T, Kikkawa F, Oguchi H, Nakashima N, Ishizuka T, Furuhashi Y, Hattori S, Kuzuya K, Ohta M, Arii Y, Tomoda Y: Clinical remission criteria for epithelial carcinoma of the ovary. Gynecol Oncol 1993;48:342–348.
- Tokuhashi Y, Kikkawa F, Tamakoshi K, Suganuma N, Kuzuya K, Arii Y, Kawai M, Hattori S, Kobayashi I, Nakashima N, Tomoda Y: A randomized trial of cisplatin, vinblastine, and bleomycin versus cyclophosphamide, aclacinomycin, and cisplatin in epithelial ovarian cancer. Oncology 1997;54:281–286.
Gershenson DM, Morris M, Burke TW, Levenback C, Kawanagh JJ, Fromm GL, Silva EG, Warner DW, Wharton JT: Combined cisplatin and carboplatin chemotherapy for treatment of advanced epithelial ovarian cancer. 1995;58:349–355.
- Kaye SB, Lewis C, Paul J, Duncan ID, Gordon HK, Kitchener HC, Cruickshank DJ, Atkinson RJ, Soukop M, Rankin EM, Cassidy J, Davis JA, Reed NS, Crawford SM, MacLean A, Swapp GA, Sarkar TK, Kennedy JH, Symonds RP: Randomized study of two doses of cisplatin and cyclophosphamide in epithelial ovarian cancer. Lancet 1992;340:329–333.
- Kaye SB, Cassidy PJ, Lewis CR, Duncan ID, Gordon HK, Kitchener HC, Crickshank DJ, Atkinson RJ, Soukop M, Rankin EM, Davis JA, Reed NS, Crawford SM, MacLean A, Parkin D, Sarkar TK, Kennedy J, Symonds RP: Mature results of a randomised trial of two doses of cisplatin for the treatment of ovarian cancer. J Clin Oncol 1996;14:2113–2119.
- McGuire WP, Hoskins WJ, Brady MF, Homesley HD, Creasman WT, Berman ML, Ball H, Berek JS, Woodward J: Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: A Gynaecological Oncology Group Study. J Clin Oncol 1995;13:1589–1599.
- Conte PF, Bruzzone M, Carnino F, Chiara S, Donadio M, Facchini V, Fioretti P, Foglia G, Gadducci A, Gallo L, et al: Carboplatin, doxorubicin and cyclophosphamide versus cisplatin, doxorubicin and cyclophosphamide: A randomized trial in stage III–IV epithelial ovarian carcinoma. J Clin Oncol 1991;9:658–663.
- Alverts DS, Green S, Hannigan EV, O’Toole R, Novack DS, Anderson P, Surwit EA, Nahhas WA, Jolles CJ: Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 1992;10:706–717.
Meerpohl HG, Sauerbrei W, Kuhnle H, Schmacher M, Pfleiderer A: Randomized study comparing carboplatin/cyclophosphamide and cisplatin/cyclophosphamide as first-line treatment in patients with stage III/IV epithelial ovarian cancer and small volume disease. Gynecol Oncol 1997;66:75–84.
- Fanning J, Hilgers RD: High-dose cisplatin carboplatin chemotherapy in primary advanced epithelial ovarian cancer. Gynecol Oncol 1993;51:182–186.
McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1966;334:1–6.
Muggia FM, Braly PS, Brady MR, et al: Phase III trial of cisplatin or paclitaxel, versus their combination in suboptimal stage III and IV epithelial ovarian cancer: Gynecologic Oncology Group Study No. 132. Proc Am Soc Clin Oncol 1997;16:1258.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.